Ivim Health Supports the Outsourcing Facilities Association's Appeal of Court Ruling That Further Restricts Access to Compounded GLP-1 Medications

Recent Federal Court Ruling Denying Request for an Injunction Will Endanger Patients by Limiting Access to Critical Weight Loss & Diabetes Drugs

COLUMBUS, Ohio, March 10, 2025 /PRNewswire/ -- Ivim Health (Ivim), a leading telehealth platform comprised of obesity medicine physicians and nurse practitioners, joins the Outsourcing Association Facilities (OFA) in publicly disagreeing with a recent federal court ruling that sided with the Biden Administration's FDA. . On March 6^th, a federal judge's decision effectively ended the compounding pharmacies' ability to make safe and effective compounded versions of tirzepatide, a prevalent weight loss and diabetes drug. This decision threatens patient access to essential treatments, will exacerbate the supply shortage, and could drive individuals toward unsafe alternatives.

"This is a devastating setback for patients across the nation who depend on these medications for weight loss treatments and for managing conditions like type 2 diabetes and obesity," said Ivim's Chief Medical Officer, Dr. Taylor Kantor. "By restricting access to these safe and effective therapies, this ruling will drastically limit options for millions of Americans, forcing them to either forgo essential care, end treatment altogether, or seek dangerous alternatives that pose serious health risks."

Ivim takes a comprehensive approach to obesity care and its customized patient-centric plans are carefully overseen by physicians, nurses, functional health coaches, and other experts. As a leading advocate for accessible healthcare, Ivim prioritizes safety, accessibility, and reliability in delivering GLP-1 medications to patients nationwide.

"There is a false narrative being widely promoted that conflates compounded GLP-1 medications with counterfeit products. Our medical providers ensure that all patients receive medications from state-licensed, FDA-regulated pharmacies. We offer our patients a safe and accessible option to utilize compounded GLP-1 medications in an environment where demand continues to outpace supply. In fact, we are concerned that this recent ruling could lead to further shortages as patients may resort to stockpiling their medications," noted Dr. Jessica Duncan, Ivim's Medical Director and a Diplomate of the American Board of Obesity Medicine In February, Ivim filed an amicus brief supporting the plaintiffs urging the court to grant a preliminary injunction in the case to enable more time for the Trump Administration's FDA to take action to ensure patient access to compounded GLP-1 medications. The company continues to call on the FDA to reverse its recent decisions and allow compounding pharmacies to supply GLP-1 medications.  As supply shortages and high costs have made these medications inaccessible to many, Ivim calls on legislators, healthcare professionals, and patient advocates to join them in opposing this recent ruling and protecting access to life-changing medicines. "We urge the new FDA administration to reconsider their predecessors' decisions and work toward a framework that prioritizes patient well-being, rather than restricting their options in favor of corporate profits," added Dr. Taylor Kantor.

The company will continue to work tirelessly to support patients and ensure they have the necessary treatments.

About Ivim Health 

Ivím Health is a healthcare institution employing nearly 100 medical providers, including Obesity Medicine Physicians and Nurse Practitioners, dedicated to the optimization of the health and wellness for patients managing cardiometabolic conditions including obesity. Ivim Health is focused on patient safety and outcomes as its personalized therapy via telehealth model is vital to make America healthy again. It addresses the national discussion surrounding the GLP-1 medication shortage (e.g., Ozempic®, Wegovy®, Saxenda®, Mounjaro®, Zepbound®) and alternative options like compounded formularies from 503A and 503B pharmacies. 

SOURCE Ivim Health